Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Philips shares soar on $1.1bn DOJ settlement
(Sharecast News) - Koninklijke Philips, the Dutch healthcare giant, has finally reached a settlement with US regulators over a Respironics product recall back in 2021 worth $1.1bn, causing shares to soar by more than a third on Monday morning. The news follows a so-called consent decree agreed earlier this month with the Department of Justice and Food and Drug Administration, which restricts the manufacture and sale of certain sleep therapy and respiratory devices.
The company's chief executive Roy Jakobs called recent developments "significant milestones and provide further clarity on the way forward for Philips".
By 1040 in Amsterdam, the stock was up 34% at €26.53 - a level not seen since April 2022.
Respironics initiated a voluntary recall "of significant scale" in June 2021 after finding that the soundproofing foam used in certain devices might degrade into particles that could be ingested or inhaled by users. According to FDA data, more than 15m devices were recalled altogether.
On Monday, Philips said it had reached a litigation settlement with the DOJ worth $1.1bn, with payments expected in 2025 and a €982m provision being recognised in the first quarter.
Philips also concluded an agreement with insurers to pay the company €540m to cover Respironics recall-related product liability claims, with the income expected in the second quarter 2024 and payments expected sometime during 2024.
"Following the remediation of sleep therapy devices and the reassuring test results to date, these important milestones on litigation, the consent decree and insurance provide Philips with a clear path forward for sustainable value creation," the company said in a statement.
Meanwhile, Philips reported a 2.4% increase in group sales to €4.1bn in the first quarter, though comparable order intake was down 3.8% due to weakness in China due to industry-wide anti-corruption measures initiated by the government and by subdued consumer demand.
The company reported an operating loss of €824m for the quarter, which included the Respironics provision.
"We started the year in line with our plan, with order intake growth outside China turning positive and strong margin improvement," Jakobs said.
"Supported by key innovation launches and strong focus on our execution priorities, we remain confident in our performance improvement plan for 2024."
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.